Neuland Laboratories Limited (BOM:524558)
India
· Delayed Price · Currency is INR | Market Cap | 185.32B |
| Revenue (ttm) | 15.75B |
| Net Income (ttm) | 1.79B |
| Shares Out | 12.83M |
| EPS (ttm) | 139.62 |
| PE Ratio | 103.45 |
| Forward PE | 46.49 |
| Dividend | 12.00 (0.08%) |
| Ex-Dividend Date | Jul 18, 2025 |
| Volume | 1,103 |
| Average Volume | 3,052 |
| Open | 14,750 |
| Previous Close | 14,755 |
| Day's Range | 14,399 - 14,884 |
| 52-Week Range | 10,598 - 19,748 |
| Beta | 0.09 |
| RSI | 55.20 |
| Earnings Date | May 12, 2026 |
About Neuland Laboratories
Neuland Laboratories Limited engages in the manufacture and sale of active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. It also provides custom manufacturing solutions, as well as peptide synthesis services. Neuland Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India. [Read more]
Financial Performance
In fiscal year 2025, Neuland Laboratories's revenue was 14.77 billion, a decrease of -5.24% compared to the previous year's 15.59 billion. Earnings were 2.60 billion, a decrease of -13.32%.
Financial StatementsNews
Neuland Laboratories appoints Saharsh Davuluri as CEO & MD to spearhead CDMO expansion
Neuland Laboratories has announced a significant leadership change with Saharsh Davuluri taking over as the Chief Executive Officer and Managing Director. This transition marks a new chapter for the c...
Pharma sector stocks today, Feb 17: Akums Drugs jumps 5%, Indegene up 4.29%, Neuland Labs surge 4.03%
The pharmaceutical sector stocks in India showed mixed performance on February 17, 2026, during early morning trading hours. Data is...
Neuland Laboratories Ltd (BOM:524558) Q3 2026 Earnings Call Highlights: Navigating Growth ...
Neuland Laboratories Ltd (BOM:524558) Q3 2026 Earnings Call Highlights: Navigating Growth Amidst Margin Pressures
Q3 2026 Neuland Laboratories Ltd Earnings Call Transcript
Q3 2026 Neuland Laboratories Ltd Earnings Call Transcript
Neuland Laboratories Transcript: Q3 25/26
Q3 FY26 revenue grew 11.4% year-over-year, driven by CMS projects, though gross margin declined due to product mix and absence of high-margin products. Capacity expansions and new CMS molecules are expected to drive growth, with a strong pipeline and investments in peptides positioning the business for long-term success.
Neuland Labs shares jump over 7% after stellar Q2 results: Net profit surges nearly 3x YoY
Neuland Laboratories Ltd saw its shares rally more than 7% in early trade on Monday after the company delivered a...
Neuland Labs share: Nuvama maintains buy, sees 24.5% upside after strong Q2 beat and robust CMS growth
Nuvama Institutional Equities has maintained its buy call on Neuland Laboratories Ltd and raised the target price to ₹22,130 per...
[Brokerage calls] Stocks to watch today, Nov 10, 2025: Trent, Nykaa, Bajaj Auto, Hindalco, Chola Investment, Lupin, PFC, NCC, Divi’s Labs and Neuland Labs in focus
Asian markets began the week on a steady note, with a flurry of brokerage actions setting the tone for key...
Q2 2026 Neuland Laboratories Ltd Earnings Call Transcript
Q2 2026 Neuland Laboratories Ltd Earnings Call Transcript
Neuland Laboratories Transcript: Q2 25/26
Q2 FY2026 saw a 63.7% revenue surge to INR 516 crore, led by CMS/CDMO growth and improved margins. Strong customer engagement, new capacity, and ongoing investments support a positive outlook, though risks from market volatility and uneven business remain.
Neuland Labs shares surge over 2% as exports jump 433% YoY in August
Shares of Neuland Laboratories Ltd surged more than 2% on Tuesday, trading at ₹16,041, after the company reported a stellar rise in export performance for August 2025. The pharma firm posted exports w...
Neuland Laboratories shares fall nearly 4% after weak Q1 results
Shares of Neuland Laboratories fell nearly 4% on Friday, August 1, closing at ₹12,761, after the company reported disappointing Q1FY26 results. The pharmaceutical firm posted a net profit of ₹13.90 cr...
Neuland Laboratories Transcript: Q1 25/26
Q1 FY26 saw a 32.4% revenue decline and margin compression due to uneven order flow, but management remains optimistic about strong FY26 growth as new capacities and commercial molecules ramp up. Peptide investments and CMS pipeline expansion are on track.
Over 40 stocks trade ex-dividend today; Kotak Mahindra Bank, Bharti Airtel, Cummins, Dabur, Intellect Design, Birlasoft, Neuland Labs in focus
A large number of companies are trading ex-dividend today, July 18, ahead of their scheduled record dates for dividend payouts. Some notable names include Bharti Airtel, Cummins India, Dabur, Birlasof...
Neuland Laboratories share price drops 5% as Q4 EBITDA falls 52.3% YoY to Rs 51 crore
Neuland Laboratories witnessed a sharp decline in its share price, falling nearly 5% after the company reported a disappointing set of numbers for the fourth quarter. As of 9:30 AM, the shares were tr...
Neuland Laboratories Transcript: Q4 24/25
Q4 and FY25 saw revenue and profit declines due to product mix and lifecycle effects, but strong free cash flow and reduced net debt position the company for growth. New capacity and product launches are expected to drive a rebound in FY26, with CMS and GDS segments both set to grow.
Neuland Laboratories receives one FDA observation following inspection of Unit 2 facility in Telangana
Neuland Laboratories Ltd. has announced that the United States Food and Drug Administration (US FDA) recently conducted an inspection of its Unit 2 manufacturing facility located in Pashamylaram villa...
Neuland Laboratories Transcript: Q3 24/25
Q3 saw modest revenue growth and a strong profit after tax due to an exceptional gain, though margins declined year-over-year. FY25 is expected to be flat, with growth resuming in FY26, supported by capacity expansion and a robust order pipeline. Major investments in peptides and improved ESG ratings highlight strategic progress.
Neuland Laboratories shares drop 6% as Q3 EBITDA falls 29% YoY
Neuland Laboratories saw its shares drop 6% after reporting mixed financial results for the third quarter. As of 9:23 AM, the shares were trading 6.04% lower at Rs 13,786.90. While the company’s reven...
Neuland Laboratories Q3 FY25 Results: Net Profit surges 24.9% YoY, Revenue flat at Rs 398.03 crore
Neuland Laboratories Limited reported its financial performance for the quarter ended December 31, 2024, showcasing a strong increase in net profit and stable revenue growth, driven by operational eff...
Neuland Labs shares surge 3% after Rs 342 crore capex plan approval
Neuland Labs shares surged 3% after the company announced a ₹342 crore capital expenditure plan aimed at bolstering its manufacturing capabilities to meet increasing market demand. The investment focu...
Top stocks to watch in trade today: Tech Mahindra, JSW Group, Neuland Labs, Railtel, PNB Housing and more
Indian stock markets are poised for a bullish opening today, as indicated by GIFT Nifty futures. This optimism comes after a mixed session yesterday, where the BSE Sensex surged by 1,235 points (1.60%...
Neuland Labs board approves Rs 342 crore capital expenditure
Neuland Laboratories has recently informed exchanges that its Board has approved a ₹342 crore capital expenditure plan to boost its manufacturing capabilities and meet growing demand. Key Projects: Un...
Mixed trends in November CDRMO exports, prefer Syngene and Neuland Labs over Divis Labs and Laurus Labs
Goldman Sachs notes mixed trends in November for Indian contract development and manufacturing organizations (CDMOs). Monthly export figures showed variability, with Neuland Labs recording a sharp 276...
Neuland Labs exports surge threefold YoY in November, 43.1% MoM growth
Neuland Labs reported exceptional export performance in November 2024, with exports growing threefold year-over-year (YoY). The company also witnessed robust month-on-month (MoM) growth of 43.1%, posi...